Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Mark R Underwood"'
Autor:
Felix DeAnda, Kendra E Hightower, Robert T Nolte, Kazunari Hattori, Tomokazu Yoshinaga, Takashi Kawasuji, Mark R Underwood
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e77448 (2013)
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings
Externí odkaz:
https://doaj.org/article/c236911bda2245a0833c118568cf3e4c
Autor:
Charlotte-Paige Rolle, Mezgebe Berhe, Tulika Singh, Roberto Ortiz, Anson Wurapa, Moti Ramgopal, Dushyantha T Jayaweera, Peter A Leone, Jessica E Matthews, Michael Cupo, Mark R Underwood, Konstantinos Angelis, Brian R Wynne, Deanna Merrill, Christopher Nguyen, Jean van Wyk, Andrew R Zolopa
Publikováno v:
Open Forum Infectious Diseases. 10
BackgroundWe assessed the efficacy and safety of dolutegravir/lamivudine (DTG/3TC) in a US test-and-treat setting at a secondary 48-week time point of the multicenter, single-arm, phase IIIb STAT study.MethodsParticipants were eligible adults newly d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ba11ab6a80a3b2169a20e556ad0bf79
https://doi.org/10.1093/ofid/ofad101
https://doi.org/10.1093/ofid/ofad101
Autor:
Martin Gartland, Juan Sierra Madero, Andrea Antinori, Brian Wynne, Jean van Wyk, Pedro Cahn, Keith A. Pappa, Choy Y. Man, Pierre-Marie Girard, Mark R. Underwood, Daisy J. Brandon, Lloyd Curtis, Roberto Ortiz, Jose R. Arribas, Chien-Ching Hung, Jürgen K. Rockstroh, Michael Aboud, Jörg Sievers, Amanda Clarke, Rimgaile Urbaityte, Kimberly Y. Smith
Publikováno v:
AIDS (London, England)
To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2.Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c95c4f7bbb6ea9e2c37a74a9b42beb86
https://doi.org/10.1097/qad.0000000000003070
https://doi.org/10.1097/qad.0000000000003070
Autor:
Moti Ramgopal, Mark R. Underwood, Andrew R. Zolopa, Brian Wynne, Tulika Singh, Mezgebe Berhe, Marybeth Dalessandro, Jessica E. Matthews, Jean van Wyk, Konstantinos Angelis, Peter A. Leone, Charlotte-Paige Rolle, Anson K Wurapa, Deanna Merrill, Roberto Ortiz, Christopher Nguyen
Publikováno v:
AIDS (London, England)
Objectives Dolutegravir/lamivudine (DTG/3TC) is indicated for treatment-naive and experienced people with HIV; however, questions remain about its utility in a test-and-treat setting because of potential transmitted resistance and baseline hepatitis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5058329d456eaa0186754d612b69040
https://doi.org/10.1097/qad.0000000000002979
https://doi.org/10.1097/qad.0000000000002979
Autor:
Eugene L. Stewart, Mark R. Underwood, Joseph Horton, Michael Aboud, Keith Nangle, Judy Hopking, Kimberly Y. Smith, Ruolan Wang, Brian Wynne, Jörg Sievers
Publikováno v:
Antimicrobial Agents and Chemotherapy
At week 48 in the phase IIIb DAWNING study, the integrase strand transfer inhibitor (INSTI) dolutegravir plus 2 nucleoside reverse transcriptase inhibitors demonstrated superiority to ritonavir-boosted lopinavir in achieving virologic suppression in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0bca41c5fa9d56ebdffb9d48f1b7b62
https://doi.org/10.1128/aac.01643-21
https://doi.org/10.1128/aac.01643-21
Autor:
Kati Vandermeulen, David Baker, Johannes R. Bogner, Mark R. Underwood, Jessica E. Matthews, Brian Wynne, David Parks, Konstantinos Angelis, Kimberly Y. Smith, Kimberly K. Adkison, Elizabeth A. Blair, Michael Aboud, Marie-Aude Khuong-Josses, Lesley P Kahl, Daniel Podzamczer, Martin Gartland, Chloe Orkin
Publikováno v:
The Lancet HIV. 6:e576-e587
Summary Background Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to continuing a standard three-drug or four-drug antiretroviral regimen fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae4be9cc30cd94a140c535d749689c7b
https://doi.org/10.1016/s2352-3018(19)30149-3
https://doi.org/10.1016/s2352-3018(19)30149-3
Autor:
Elmira Mamedova, Maria Claudia Nascimento, Fujie Zhang, Marcelo H. Losso, Jörg Sievers, Richard Kaplan, Judy Hopking, Dannae Brown, Mark R. Underwood, Ploenchan Chetchotisakd, Johannes Lombaard, Kimberly Y. Smith, Yogesh Punekar, Michael Aboud, Martin Gartland, Carlos Brites, José A Hidalgo
Publikováno v:
The Lancet Infectious Diseases. 19:253-264
Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8caa2f52174153e6135cae1a917506
https://doi.org/10.1016/s1473-3099(19)30036-2
https://doi.org/10.1016/s1473-3099(19)30036-2
Autor:
Pedro Cahn, Rimgaile Urbaityte, Choy Y. Man, Jean van Wyk, Mark R. Underwood, Kimberly Y. Smith, Roberto Zajdenverg, Jörg Sievers, Juan Sierra Madero, Jose R. Arribas
Publikováno v:
Brazilian Journal of Infectious Diseases, Vol 25, Iss, Pp 101259-(2021)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::848781625772372cc3c0c069549912f3
http://www.sciencedirect.com/science/article/pii/S141386702030386X
http://www.sciencedirect.com/science/article/pii/S141386702030386X
Autor:
Brian Wynne, Rafael M. Rubio, Kati Vandermeulen, David Baker, Lesley P Kahl, Johannes R. Bogner, Jessica E. Matthews, David A Parks, Jean van Wyk, Konstantinos Angelis, Marie-Aude Khuong-Josses, Kimberly Y. Smith, Mark R. Underwood, Ruolan Wang, Chloe Orkin, Martin Gartland, Maria-Claudia Nascimento
Publikováno v:
Journal of Acquired Immune Deficiency Syndromes (1999)
Background: The SWORD trials showed that in participants who achieved virologic suppression taking 3-drug or 4-drug regimens, switching to the 2-drug regimen dolutegravir plus rilpivirine was noninferior in maintaining HIV-1 RNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb290407f2546269dda263fd00dc7f85
https://pubmed.ncbi.nlm.nih.gov/32675772
https://pubmed.ncbi.nlm.nih.gov/32675772
Autor:
Brian Wynne, Choy Y. Man, Daisy J. Brandon, Andrea Antinori, Jose R. Arribas, Pedro Cahn, Pierre-Marie Girard, Mark R. Underwood, Kimberly Y. Smith, Amanda Clarke, Juan Sierra Madero, Jean van Wyk, Jörg Sievers, Martin Gartland, Rimgaile Urbaityte, Michael Aboud, Keith A. Pappa, Chien-Ching Hung, Allan R Tenorio, Roberto Ortiz, Jürgen K. Rockstroh
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 83(3)
Two-drug regimens (2DRs) can potentially reduce long-term cumulative drug exposure and decrease treatment-associated costs for HIV-1–infected individuals, who require lifelong therapy.1 The core antiretroviral agent in a 2DR must have high potency
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e12488d59ced9e7aed80902e5e729b9d
https://pubmed.ncbi.nlm.nih.gov/32530908
https://pubmed.ncbi.nlm.nih.gov/32530908